Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 98.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,025 shares of the medical research company's stock after selling 62,335 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC's holdings in Edwards Lifesciences were worth $76,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in EW. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth about $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter worth $30,000. Roble Belko & Company Inc purchased a new position in Edwards Lifesciences during the fourth quarter worth $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on EW. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $73.00 to $80.00 in a research report on Thursday. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $79.45.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,153,526.69. This represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,853 shares of company stock worth $5,163,062. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Up 1.2 %

Shares of EW traded up $0.93 during midday trading on Friday, hitting $76.06. 6,330,152 shares of the company's stock traded hands, compared to its average volume of 4,990,356. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.71 billion, a price-to-earnings ratio of 10.91, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm's fifty day moving average is $70.94 and its 200-day moving average is $71.09.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period last year, the business posted $0.66 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.